News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Boehringer Ingelheim Corporation Sex Pill, Flibanserin May Not Aid Women, FDA Staff Say
June 16, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Boehringer Ingelheim GmbH’s sexual desire drug flibanserin may not be effective or safe, according to U.S. regulators weighing whether to approve the first pill designed to boost women’s libidos.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Boehringer Ingelheim
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Government
Court Orders Restoration of Canceled NIH Grants, Calls Cuts ‘Appalling’
June 17, 2025
·
2 min read
·
Tristan Manalac
CDC
CDC Scientist Resigns in Protest as Kennedy Reshapes Vaccine Regulation
June 17, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Partner-Seeking Biotechs Find Plenty of Hands To Shake as BIO2025 Kicks Off
June 16, 2025
·
2 min read
·
Jef Akst
Vaccines
As New CDC Vaccine Advisors Gear Up for First Meeting, Experts Ask, ‘Where’s Cassidy?’
June 12, 2025
·
4 min read
·
Heather McKenzie